Abstract:6042 Background: The development of biomarkers that reliably predict response to anti-PD-1 mAb therapy (IO) is a critical need. Small (30-150 nm) extracellular vesicles (sEV), aka exosomes, are “molecular mimics” of their parent cells. In cancer, plasma sEV are mixtures of tumor-derived exosomes (TEX) and vesicles produced by non-malignant cells. We conducted a retrospective study of R/M HNSCC patients treated with IO to evaluate sEV as predictive biomarkers. Methods: We evaluated sEV in plasma of R/M HNSCC patients (n = 24) obtained just prior to initiation of IO. Precleared ultrafiltered plasma was used to isolate total plasma sEV by size exclusion chromatography. Total plasma sEV were separated into two subsets, T cell-derived CD3(+) sEV and TEX-enriched CD3(-) sEV by immunocapture with anti-CD3 mAb. On-bead flow cytometry was used to estimate relative levels of proteins carried on the sEV surface. Specifically, the CD3(-) fraction was evaluated for stimulatory (stim; CD40, CD40L, OX40, OX40L, CD80) and suppressive (supp; TGFb, CTLA4, FasL, PD-L1, PD-1) proteins. Differences between responders (CR/PR/SD) and non-responders (PD) were assessed using Wilcoxon-Mann-Whitney test. Multivariate Cox proportional hazards regression was used to evaluate the relationship between the pre-treatment sEV characteristics and outcome. Results: Mean age was 62, 46% had oropharynx (82% HPV+), 17% oral cavity and 29% had larynx/hypopharynx primary. Treatment indication for IO was 46% platinum failure, remainder first line. Best response: 17% PR, 29% SD, and 54% PD. Median PFS and OS were 5.3 and 16.2 months, respectively. Total sEV protein level was not associated with efficacy. Total CD3(+) sEV level was low overall and did not correlate with lymphocyte count or neutrophil/lymphocyte ratio. High CD3(+) sEV level was associated with better OS [HR: 0.16 (95% CI 0.04-0.59), P = 0.007] and PFS [HR: 0.16 (95% CI 0.04-0.58), P = 0.005] but not response. While total TEX and levels of individual stim and supp proteins carried by TEX were not predictive of response, an increased supp/stim ratio was (P = 0.02). Importantly, high TEX supp score and stim score were both associated with better OS [HR: 0.19 (95% CI 0.05-0.77), P = 0.02, and HR: 0.26 (95% CI 0.07-0.95), P = 0.04, resp.]. High PD-L1, but not PD-1 on TEX, was associated with better OS [HR: 0.15 (95% CI 0.04-0.56), P = 0.005]; and PFS: HR: 0.33 (95% CI 0.11-0.94), P = 0.04]. Conclusions: Evaluation of two sEV subsets, T cell-derived-CD3(+) sEV and TEX-enriched CD3(-) sEV, indicated their potential utility as predictive biomarkers with IO. High T cell-derived sEV, TEX supp/stim ratio, and TEX PD-L1 expression levels were independently associated with significantly increased efficacy with IO. Our study uniquely analyzed the predictive value of plasma sEv subsets in IO treated R/M HNSCC patients, and evaluation in a larger cohort is warranted.

HRS regulates small extracellular vesicle PD-L1 secretion and is associated with anti-PD-1 treatment efficacy

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

EZH2 Inhibition Activates Dsrna-Interferon Axis Stress and Promotes Response to PD-1 Checkpoint Blockade in NSCLC

HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation

HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors

Hypoxia regulates small extracellular vesicle biogenesis and cargo sorting through HIF-1α/HRS signaling pathway in head and neck squamous cell carcinoma

SPHK1 Promotes HNSCC Immune Evasion by Regulating the MMP1-PD-L1 Axis

Small extracellular vesicles as biomarkers of response in recurrent/metastatic HNSCC patients treated with immunotherapy

CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment

Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC.

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Immunosuppressive Effect of Small Extracellular Vesicle PD-L1 is Restricted by Co-Expression of CD80

Soluble PD-L1 As a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients with EGFR Mutations.

EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC

PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma

Spatiotemporal characteristics of tissue derived small extracellular vesicles is associated with tumor relapse and anti-PD-1 response

Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage

RRS1: an prognostic and diagnostic biomarker of hepatocellular carcinoma from a comprehesive analysis

PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma

PD-1/CD80+ Small Extracellular Vesicles from Immunocytes Induce Cold Tumours Featured with Enhanced Adaptive Immunosuppression

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients